MA54960A - Dérivé de 7h-pyrrolo [2,3-d] pyrimidine-4-amine - Google Patents

Dérivé de 7h-pyrrolo [2,3-d] pyrimidine-4-amine

Info

Publication number
MA54960A
MA54960A MA054960A MA54960A MA54960A MA 54960 A MA54960 A MA 54960A MA 054960 A MA054960 A MA 054960A MA 54960 A MA54960 A MA 54960A MA 54960 A MA54960 A MA 54960A
Authority
MA
Morocco
Prior art keywords
pyrrolo
pyrimidine
amine derivative
amine
derivative
Prior art date
Application number
MA054960A
Other languages
English (en)
Inventor
Hirokazu Fuchida
Shoki Hara
Hidefumi Kasuga
Yu KOBAYAKAWA
Takashi Mizutani
Yoshio Ogino
Fuyuki Yamamoto
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of MA54960A publication Critical patent/MA54960A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA054960A 2019-02-15 2020-02-14 Dérivé de 7h-pyrrolo [2,3-d] pyrimidine-4-amine MA54960A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2019025844 2019-02-15

Publications (1)

Publication Number Publication Date
MA54960A true MA54960A (fr) 2021-12-22

Family

ID=72044229

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054960A MA54960A (fr) 2019-02-15 2020-02-14 Dérivé de 7h-pyrrolo [2,3-d] pyrimidine-4-amine

Country Status (14)

Country Link
US (1) US11786534B2 (fr)
EP (1) EP3925669A4 (fr)
JP (1) JP6960064B2 (fr)
KR (1) KR102645237B1 (fr)
CN (1) CN113453764B (fr)
AU (1) AU2020221744B2 (fr)
BR (1) BR112021015813A2 (fr)
CA (1) CA3130049C (fr)
MA (1) MA54960A (fr)
MX (1) MX2021009752A (fr)
PH (1) PH12021551957A1 (fr)
SG (1) SG11202108648TA (fr)
TW (1) TWI828861B (fr)
WO (1) WO2020166680A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3250005A1 (fr) 2022-04-22 2025-06-17 Taiho Pharmaceutical Co., Ltd. Procédé de production d'un dérivé de 7h-pyrrolo[2,3-d]pyrimidine-4-amine
KR20240163140A (ko) 2022-04-22 2024-11-18 다이호야쿠힌고교 가부시키가이샤 7H-피롤로[2,3-d]피리미딘-4-아민 유도체의 결정
TW202529752A (zh) * 2023-09-29 2025-08-01 日商大鵬藥品工業股份有限公司 7H-吡咯並[2,3-d]嘧啶-4-胺衍生物的結晶
TW202532073A (zh) * 2023-12-13 2025-08-16 日商大鵬藥品工業股份有限公司 以N-(4-(4-胺基-6-乙炔基-5-(喹啉-3-基)-7H-吡咯并[2, 3-d]嘧啶-7-基)雙環[2. 2. 1]庚烷-1-基)-5-甲基吡-2-甲醯胺或其鹽為有效成分之腦移行性腫瘤治療劑

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007075554A2 (fr) 2005-12-19 2007-07-05 Osi Pharmaceuticals, Inc. Traitement combine avec une composition d’inhibiteur de proteine kinase heterobicyclique a noyau 6,6-bicyclique et d'agents anticancereux
US8575164B2 (en) 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
WO2013118817A1 (fr) * 2012-02-07 2013-08-15 大鵬薬品工業株式会社 Composé de quinolyl pyrrolopyrimidine ou son sel
MX2015006168A (es) * 2012-11-15 2015-08-10 Pharmacyclics Inc Compuestos de pirrolopirimidina como inhibidores de quinasas.
JP6427599B2 (ja) 2014-05-19 2018-11-21 チャンスー ヘンルイ メディシン カンパニー,リミテッド チロシンキナーゼ阻害剤としての置換エチニルヘテロ二環式化合物
JOP20190073A1 (ar) 2016-10-31 2019-04-07 Taiho Pharmaceutical Co Ltd مثبط انتقائي لمستقبل عامل نمو بشروي (egfr) لطافر إدخال exon 20

Also Published As

Publication number Publication date
EP3925669A1 (fr) 2021-12-22
CN113453764B (zh) 2024-04-16
TW202045509A (zh) 2020-12-16
JP6960064B2 (ja) 2021-11-05
BR112021015813A2 (pt) 2021-10-13
US20220160719A1 (en) 2022-05-26
AU2020221744B2 (en) 2022-06-23
KR102645237B1 (ko) 2024-03-07
KR20210116598A (ko) 2021-09-27
PH12021551957A1 (en) 2022-05-23
WO2020166680A1 (fr) 2020-08-20
SG11202108648TA (en) 2021-09-29
CA3130049C (fr) 2024-04-16
US11786534B2 (en) 2023-10-17
CN113453764A (zh) 2021-09-28
MX2021009752A (es) 2021-09-08
JPWO2020166680A1 (ja) 2021-11-04
CA3130049A1 (fr) 2020-08-20
TWI828861B (zh) 2024-01-11
EP3925669A4 (fr) 2022-10-26
AU2020221744A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
MA47500A (fr) Dérivés de pyrrolo [1,2-b]pyridazine
IL276802B1 (en) Transduced 2,1-dihydro-3h-pyrazolo[4,3-d]pyrimidine-3-ones
EP3980010A4 (fr) Composés de pyrazolo[1,5-a]pyrimidine 2,3,5-trisubstitués
IL260923B (en) History of pyrazolo[5,1-a]pyrazin-4-yl as jak inhibitors
HUE051424T2 (hu) RET kináz inhibitor szubsztituált pirazolo[1,5-a]piridin vegyületek
DK3523302T3 (da) Substituerede pyrazolo[1,5-A]pyridin-forbindelser som RET-kinase-inhibitorer
IL289456A (en) Eif4e-inhibiting 4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine compounds
ZA202105338B (en) Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as tlr7 agonist
IL290445A (en) [1,2,4]triazolo[1,5-c]quinazolin-5-amines
MA54960A (fr) Dérivé de 7h-pyrrolo [2,3-d] pyrimidine-4-amine
EP3744723A4 (fr) Composé macrocyclique de pyrazolo [1,5-a]pyrimidine substitué
LT3820872T (lt) Pirolo[1,2-b]piridazino dariniai
IL262673A (en) A pyrazolo[5,1-a]pyrimidine compound
DK3679042T3 (da) Imidazo[1,5-A]pyrazin-derivater som PI3Kdelta-inhibitorer
EP3196199A4 (fr) N-(pyrrolidin-3-yl)-7h-pyrrolo[2,3-d]pyrimidine-4-amine substituée utilisée en tant qu'inhibiteur de la janus kinase
DK3459953T3 (da) Hidtil ukendt 5h-pyrrolo[2,3-d]pyrimidin-6(7h)-on-derivat
EP3903788A4 (fr) Composé macrocyclique de pyrazolo[1,5-a] pyrimidine
HUE052997T2 (hu) JAK kináz inhibitor pirazol[1,5-a]pirimidin származékok